NDLI: MUTANT IDH1 SUPPRESSES APOPTOSIS REGULATOR PAR-4 IN GLIOMAS

Content Provider	PubMed Central
Author	Craig, Horbinski Liu, Yinxing Gilbert, Misty R. Kyprianou, Natasha
Copyright Year	2014
Abstract	BACKGROUND: Glioma-associated mutations in isocitrate dehydrogenase 1 (IDH1) alter its catalytic properties, leading to the production of D-2-hydroxyglutarate (D-2-HG). This promotes hypermethylation and inhibits differentiation, but its full range of effects remains unclear. In pediatric acute myeloid leukemias, the presence of mutant IDH1 is associated with upregulation of Prostate apoptosis response-4 (Par-4), which promotes cancer-selective apoptosis. Because of this, and because very little work has been done studying Par-4 in gliomas, we tested the effect of mutant IDH1 on Par-4 in these tumors. METHODS: Par-4 expression was measured via western immunoblots in cell cultures and immunohistochemistry in paraffin-embedded tumor tissue microarrays. Par-4 mRNA levels and stability were measured using RT-PCR, cycloheximide, and actinomycin D assays.Par-4 promoter activity was studied with a luciferase reporter assay. Glioblastoma (GBM) cell lines and patient-derived stem cells were infected via lentivirus with either the Selective for Apoptosis induction in Cancer cells (SAC) domain of Par-4 or with control plasmid, for in vitro studies as well as prior to intracerebral injection in nude mice. External validation datasets included The Cancer Genome Atlas (TCGA) and the REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT). RESULTS: In vitro treatment with exogenous unmodified D-2-HG or expression of R132H IDH1 downregulates Par-4 in GBM cells. This occurs by inhibition of Par-4 promoter activity as well as by acceleration of Par-4 mRNA degradation, but not direct promoter hypermethylation. In patients, Par-4 expression is markedly lower in IDH1-mutant high grade gliomas, both in our cohort (P = 0.003) as well as in GBMs from TCGA (P = 0.008). Expression of the SAC domain of Par-4 induces apoptosis in GBM cells. When GBM stem cell intracranial xenografts express SAC, mice have longer median survival compared to controls (30 vs 23 days, P = 0.016). Among high-grade gliomas that are IDH1 wild-type, those that express Par-4 have significantly longer median survival (18.4 versus 8.0 months, P = 0.002), a finding confirmed in external GBM cohorts. CONCLUSIONS: These data suggest that a.) Mutant IDH1 and D-2-HG can affect protein expression independent of direct gene hypermethylation, b.) Suppression of Par-4 may contribute to IDH1-mutant tumorigenesis; c.) While this might seem to be a paradoxical effect of mutant IDH1 given its association with better prognosis, not all its activities will be “favorable” or the mutation would not be so prevalent in gliomas; d.) Regardless of IDH1 status, Par-4 may be an effective sensitizer of gliomas to apoptosis. SECONDARY CATEGORY: Tumor Biology.
Related Links	http://dx.doi.org/10.1093/neuonc/nou206.21
Starting Page	6
File Format	PDF
ISSN	15228517
e-ISSN	15235866
Journal	Neuro-Oncology
Issue Number	Suppl 3
Volume Number	16
Language	English
Publisher	Oxford University Press
Publisher Date	2014-07-01
Access Restriction	Open
Rights Holder	Oxford University Press
Subject Keyword	Cancer Research Oncology Clinical Neurology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Neurology (clinical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

METABOLIC IMAGING BIOMARKERS FOR MUTANT IDH1 GLIOMAS

OPTIMIZATION OF DEMETHYLATING THERAPY FOR IDH1 MUTANT GLIOMAS

ET-08DEMETHYLATING THERAPY INDUCES DIFFERENTATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Response to “Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas”

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas

Disruption of wild type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas

MUTANT IDH1 SUPPRESSES APOPTOSIS REGULATOR PAR-4 IN GLIOMAS

Similar Documents

METABOLIC IMAGING BIOMARKERS FOR MUTANT IDH1 GLIOMAS

OPTIMIZATION OF DEMETHYLATING THERAPY FOR IDH1 MUTANT GLIOMAS

ET-08DEMETHYLATING THERAPY INDUCES DIFFERENTATION AND THERAPEUTIC RESPONSE IN IDH1 MUTANT MALIGNANT GLIOMAS

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Response to “Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas”

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas

Disruption of wild type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status

Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas

MUTANT IDH1 SUPPRESSES APOPTOSIS REGULATOR PAR-4 IN GLIOMAS